Search results for " type 2 diabetes mellitus"

showing 3 items of 33 documents

Clinical inertia is the enemy of therapeutic success in the management of diabetes and its complications: A narrative literature review

2020

AbstractDiabetes mellitus is a chronic disease characterized by high social, economic and health burden, mostly due to the high incidence and morbidity of diabetes complications. Numerous studies have shown that optimizing metabolic control may reduce the risk of micro and macrovascular complications related to the disease, and the algorithms suggest that an appropriate and timely step of care intensification should be proposed after 3 months from the failure to achieve metabolic goals. Nonetheless, many population studies show that glycemic control in diabetic patients is often inadequate. The phenomenon of clinical inertia in diabetology, defined as the failure to start a therapy or its i…

medicine.medical_specialtyEndocrinology Diabetes and MetabolismPopulationTherapeutic inertiaDiseaseReviewDiabetes mellitusEpidemiologyType 2 diabetes mellitusInternal MedicinemedicineIntensive care medicineeducationlcsh:RC620-627Therapeutic inertiaGlycemiceducation.field_of_studyClinical inertia Diabetes care Italian association of medical diabetologists Therapeutic inertia Type 2 diabetes mellitusbusiness.industryType 2 Diabetes Mellitusmedicine.diseaselcsh:Nutritional diseases. Deficiency diseasesClinical inertiaMetabolic control analysisItalian association of medical diabetologistsbusinessDiabetes care
researchProduct

Incretin-Based Therapies, Glucometabolic Health and Endovascular Inflammation

2013

Incretin peptides are a group of gastrointestinal hormones that play a prominent role in the regulation of glucose metabolism. Incretin-based therapies (IBTs) have recently emerged as an important treatment option for patients with type 2 diabetes mellitus (T2DM). These pharmaceutical agents may be specially well suited for patients who are overweight or obese with primarily post-meal glucose peaks, and in whom traditional first-line oral agents have failed to maintain adequate glycemic control. There are 2 classes of IBTs: the dipeptidyl peptidase-4 (DPP-4) inhibitors and the glucagon-like peptide 1 (GLP-1) receptor agonists. The ultimate effect of both types of agents is to augment GLP-1 …

medicine.medical_specialtyLipoproteinsIncretin type 2 diabetes mellitus metabolic syndrome lipoproteinsIncretinBiologyIncretinsGlucagon-Like Peptide-1 ReceptorWeight lossDiabetes mellitusInternal medicineDrug DiscoverymedicineAnimalsHumansGlucose homeostasisAdiponectin secretionLipoproteinInflammationPharmacologyDipeptidyl-Peptidase IV InhibitorsDrug Discovery3003 Pharmaceutical ScienceMedicine (all)digestive oral and skin physiologyGlucagon secretionType 2 Diabetes MellitusIncretinAtherosclerosismedicine.diseaseMetabolic syndromeType 2 diabetes mellituGlucoseEndocrinologyDiabetes Mellitus Type 2Metabolic syndromemedicine.symptomCurrent Pharmaceutical Design
researchProduct

Gestational diabetes and the metabolic syndrome: Can obesity and small, dense low density lipoproteins be key mediators of this association?

2013

Gestational diabetes mellitus (GDM) represents a condition of glucose intolerance with first appearance or recognition at the time of a pregnancy, associated with an inadequate pancreatic response to the advanced insulin resistance of the later stages of pregnancy, and accompanied by enhancing β-cell mass and secretion of insulin. Women who had GDM exhibit a higher risk for later advent of type 2 diabetes mellitus (T2DM) and cardiovascular diseases (CVD). Additionally, previous GDM has been proposed as independently correlated with higher risk for development of atherosclerosis in a healthy population, similar to the metabolic syndrome (MetS) and independently of the presence of established…

medicine.medical_specialtyendocrine system diseasesPharmaceutical ScienceInsulin resistancePregnancyDiabetes mellitusInternal medicineHumansMedicineObesityMetabolic SyndromePregnancybusiness.industryObstetricsnutritional and metabolic diseasesType 2 Diabetes Mellitusmedicine.diseaseObesityLipoproteins LDLGestational diabetesDiabetes GestationalEndocrinologyFemaleMetabolic syndromecardiovascular disease cardiovascular risk gestational diabetes mellitus metabolic syndrome small dense low-density lipoprotein type 2 diabetes mellitusbusinessPostpartum periodBiotechnology
researchProduct